Business, energy, technology, markets and global industry news from Business News Today

androgen receptor inhibitors

PharmaDeviceNews androgen receptor inhibitors
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Pharma & Biotech

Real-world data meets legal limits as Bayer targets ERLEADA claims in prostate cancer

Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.

Read More